169 related articles for article (PubMed ID: 34591688)
1. PET-CT for the diagnosis and treatment of primary musculoskeletal tumors in Chinese patients - experience from 255 patients in a single center.
Muheremu A; Wen T; Niu X
Br J Radiol; 2021 Dec; 94(1128):20210785. PubMed ID: 34591688
[TBL] [Abstract][Full Text] [Related]
2. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases.
Charest M; Hickeson M; Lisbona R; Novales-Diaz JA; Derbekyan V; Turcotte RE
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1944-51. PubMed ID: 19593561
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 3T diffusion-weighted MRI and
Lee SY; Jee WH; Yoo IR; Jung JY; Im SA; Chung YG; Kang JH
Br J Radiol; 2019 Oct; 92(1102):20181051. PubMed ID: 31322913
[TBL] [Abstract][Full Text] [Related]
5. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
[TBL] [Abstract][Full Text] [Related]
6. Dual-time point
Parghane RV; Basu S
Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of maximum standardized uptake value on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in bone sarcomas.
Tamam C; Tamam M
Eklem Hastalik Cerrahisi; 2018 Dec; 29(3):184-8. PubMed ID: 30376804
[TBL] [Abstract][Full Text] [Related]
9. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H
PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191
[TBL] [Abstract][Full Text] [Related]
10. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
Iagaru A; Masamed R; Chawla SP; Menendez LR; Fedenko A; Conti PS
Clin Nucl Med; 2008 Jan; 33(1):8-13. PubMed ID: 18097248
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients.
Fuglø HM; Jørgensen SM; Loft A; Hovgaard D; Petersen MM
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1416-24. PubMed ID: 22699526
[TBL] [Abstract][Full Text] [Related]
14. Combination of positron emission tomography/computed tomography and chest thin-layer high-resolution computed tomography for evaluation of pulmonary nodules: Correlation with imaging features, maximum standardized uptake value, and pathology.
Hou S; Lin X; Wang S; Shen Y; Meng Z; Jia Q; Tan J
Medicine (Baltimore); 2018 Aug; 97(31):e11640. PubMed ID: 30075545
[TBL] [Abstract][Full Text] [Related]
15. PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma.
Kandathil A; Subramaniam RM
PET Clin; 2017 Oct; 12(4):475-488. PubMed ID: 28867117
[TBL] [Abstract][Full Text] [Related]
16. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II.
Hamada K; Tomita Y; Qiu Y; Zhang B; Ueda T; Myoui A; Higuchi I; Yoshikawa H; Aozasa K; Hatazawa J
Ann Nucl Med; 2008 Oct; 22(8):699-705. PubMed ID: 18982473
[TBL] [Abstract][Full Text] [Related]
18. The role of
Subramaniam S; Callahan J; Bressel M; Hofman MS; Mitchell C; Hendry S; Vissers FL; Van der Hiel B; Patel D; Van Houdt WJ; Tseng WW; Gyorki DE
J Surg Oncol; 2021 Mar; 123(4):1081-1087. PubMed ID: 33444466
[TBL] [Abstract][Full Text] [Related]
19. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
Palmerini E; Colangeli M; Nanni C; Fanti S; Marchesi E; Paioli A; Picci P; Cambioli S; Donati D; Cevolani L; De Paolis M; Gambarotti M; Ferrari S
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):215-223. PubMed ID: 27645694
[TBL] [Abstract][Full Text] [Related]
20. Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.
Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
Medicine (Baltimore); 2015 Jul; 94(28):e1142. PubMed ID: 26181552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
